Medicaid will not cover some gender-affirming treatment for transgender minors under Trump administration policy, CBS News reports

The Trump administration has instructed states that Medicaid will not pay for certain gender-affirming treatments for transgender minors, CBS News reported on Tuesday. The report says the policy bars federal Medicaid funding for gender-affirming surgeries and hormones for children and teens who are transgender.

CBS News described the development as an administration position communicated to states through Medicaid program guidance. The practical effect, according to the report, is that states operating Medicaid programs would be required to exclude the specified treatments from federally reimbursable coverage for minors, even if they cover other categories of care under state benefit design.

The reported change would shift the responsibility for those treatments away from Medicaid’s federal cost-sharing framework. For families whose children rely on Medicaid coverage, the policy means that treatments falling within the restricted categories would not be paid through Medicaid reimbursement, creating new out-of-pocket burdens or limiting access depending on whether other insurers or state-only programs cover alternatives.

The guidance also raises enforcement and compliance questions for state Medicaid agencies. Because Medicaid is a joint federal-state program, state officials generally must comply with federal requirements tied to federal funding. CBS News reported that the administration’s position would be applied through Medicaid coverage standards for minors, which could lead states to revise coverage policies, prior authorization rules, and claims processing workflows.

The administration’s rationale, as characterized by CBS News, centers on how federal Medicaid funds may be used and which treatments the program will reimburse. The report framed the move as an effort by the federal government to set limits on Medicaid reimbursement for gender-affirming care for minors, rather than as an individual coverage decision made by clinicians or insurers case-by-case.

Opponents of restrictions on gender-affirming care have argued that such policies interfere with medical decision-making and raise civil rights concerns, and CBS News reported that advocates are likely to contest the administration’s approach. The outcome of any legal challenges or administrative disputes would depend on how the guidance is implemented by states, whether it is challenged in court, and what procedural and statutory claims are raised regarding Medicaid’s obligations and the federal government’s authority.

For now, the next steps are tied to implementation by states and to whether affected families and advocacy groups seek judicial review. States would be expected to update policies to align with the administration’s Medicaid reimbursement position for minors, and further reporting may clarify timing, the scope of exclusions, and how Medicaid will handle claims submitted after the effective implementation of the guidance.